New study aims to unravel mysterious Lung-Liver connection

NCT ID NCT07481877

Not yet recruiting Knowledge-focused Sponsor: Chinese Pulmonary Vascular Disease Research Group Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will follow 300 adults who have both a portosystemic shunt (an abnormal blood vessel connection between the liver and the rest of the body) and pulmonary hypertension (high blood pressure in the lungs). Researchers want to learn more about how common this combination is, what symptoms patients have, and how well current treatments work. The goal is to improve diagnosis and care for this specific group of patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could provide a clearer understanding of how to diagnose and manage pulmonary hypertension in patients with portosystemic shunts, potentially improving care guidelines.
What could go wrong: This is an observational study, not a treatment trial, so it won't directly test a new therapy. Results may take years and might not lead to immediate changes in patient care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PORTOSYSTEMIC SHUNT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congenital portosystemic shunt Fibrosis portal hypertension pulmonary hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PORTOSYSTEMIC SHUNT PULMONARY HYPERTENSION

More trials for these conditions

Other studies related to the condition(s) this trial covers.